India’s drug regulator on Tuesday allowed vaccine maker Serum Institute to appoint youngsters aged 7-11 years for testing US drugmaker Novavax’s COVID-19 vaccine, because the nation tries to guard youngsters from the novel coronavirus. works out.
The South Asian nation has already given greater than 870 million doses to adults amongst a inhabitants of about 1.4 billion.
A subject skilled panel of the Central Drugs Standard Control Organization mentioned, “After detailed deliberations, the committee recommended allowing enrollment of subjects in the age group of 7 to 11 years as per protocol.”
Serum Institute is already testing its COVID-19 vaccine Covovax, a home-made model of Novavax’s shot, within the age group of 12-17 and introduced security information for the preliminary 100 individuals.
The Novavax vaccine is but to be authorised by the Indian well being authorities. Earlier this month, Serum Institute head Adar Poonawalla mentioned he expects Kovovax to be authorised for folks beneath 18 in January or February subsequent yr.
So far, solely drugmaker Zydus Cadila’s DNA COVID-19 vaccine has obtained emergency use approval in India to be used in adults and kids aged 12 years and above.
.
With inputs from TheIndianEXPRESS
